For the quarter ending 2026-03-29, PFE made $14,451M in revenue. $2,687M in net income. Net profit margin of 18.59%.
| Income Statement | 2026-03-29 | 2025-12-31 | 2025-09-28 | 2025-06-29 |
|---|---|---|---|---|
| Total revenues | 14,451 | 17,557 | 16,654 | 14,653 |
| Cost of sales | 3,548 | 5,272 | 4,172 | 3,778 |
| Selling, informational and administrative expenses | 2,961 | 4,162 | 3,186 | 3,415 |
| Research and development expenses | 2,490 | 3,206 | 2,546 | 2,482 |
| Acquired in-process research and development expenses | 137 | 212 | 1,390 | 2 |
| Amortization of intangible assets | 1,183 | 1,229 | 1,223 | 1,211 |
| Restructuring charges and certain acquisition-related costs | 100 | 604 | 286 | -18 |
| Other (income)/deductionsnet | -861 | -4,515 | -517 | -739 |
| Income from continuing operations before provision/(benefit) for taxes on income | 3,170 | -1,643 | 3,334 | 3,044 |
| Provision/(benefit) for taxes on income | 461 | -2 | -216 | 141 |
| Income from continuing operations | 2,709 | -1,639 | 3,550 | 2,903 |
| Discontinued operationsnet of tax | -13 | 0 | 0 | 25 |
| Net income before allocation to noncontrolling interests | 2,696 | -1,639 | 3,550 | 2,928 |
| Less net income attributable to noncontrolling interests | 8 | 8 | 9 | 18 |
| Net income attributable to pfizer inc. common shareholders | 2,687 | -1,647 | 3,541 | 2,910 |
| Basic EPS | 0.47 | -0.29 | 0.62 | 0.51 |
| Diluted EPS | 0.47 | -0.288 | 0.62 | 0.51 |
| Basic Average Shares | 5,691,000,000 | 5,687,000,000 | 5,685,000,000 | 5,685,000,000 |
| Diluted Average Shares | 5,731,000,000 | 5,722,000,000 | 5,714,000,000 | 5,706,000,000 |
PFIZER INC (PFE)
PFIZER INC (PFE)